Advertisement

Picture EBD Group BioPharm America 2021 Digital BPA2021 650x80
Organisation › Details

Autifony Therapeutics Ltd.

Autifony Therapeutics is an independent UK based biotechnology company formed in 2011 as a spin-out from GSK, which retains equity in the company. The Company is focused on the development of high value, novel medicines to treat hearing disorders and other serious diseases of the central nervous system. It is funded by SV Health Investors, IP Group, Pfizer Ventures, International Biotechnology Trust PLC, and UCL Business plc. *

 

Period Start 2011-01-01 splitoff
  Group Autifony (Group)
  Predecessor GlaxoSmithKline (GSK) (Group)
Product Industry drug discovery
Person Person Large, Charles (Autifony 201712 CEO before CSO)
     
Region Region Stevenage, Hertfordshire
  Country United Kingdom (GB)
  Street Gunnels Wood Road
Stevenage Bioscience Catalyst
  City SG1 2FX Stevenage, Hertfordshire
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: Autifony Therapeutics Ltd.. (8/26/20). "Press Release: Autifony Therapeutics Regains Rights to Clinical Stage Kv3 Programme". Stevenage.
     
   
Record changed: 2021-03-19

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Autifony (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC B Preview Download 650x300px




» top